d nd f s l a tx - university health systemhr.universityhealthsystem.com/purchasing/pdf/918a.pdf ·...

DATE: NOVEMBER 12, 2013

UNIVERSITY HEALTH SYSTEM-BUSINESS CENTER

PURCHASING DEPARTMENT-2ND

FLOOR

355-2 SPENCER LANE

SAN ANTONIO, TX 78201

SOLICITATION: RFP-213-10-051-LAB REFERENCE LABORATORY LAB

ADDENDUM NO. 3

RE: Questions/Answers

Due: On or before Novemeber 22, 2013 at 2:00 PM CST

NOTICE TO BIDDERS:

A. Receipt of this Addendum shall be acknowledged on the Bid Form.

B. Bidders are required to sign this addendum acknowledging receipt and return a

copy by email. Corresponding email for this purpose is Michael Llanas, UHS

Purchasing, Contract Specialist, at [email protected]

C. This Addendum is part of the RFP-213-10-051-LAB documents for the above

referenced project and shall be incorporated integrally therewith.

D. Each bidder shall make necessary adjustments and submit their proposal with full

knowledge of all modifications: clarifications and supplemental data include therein.

Company Name: ________________________________________________________

__________________________________ _________________________________

Vendor Signature Date:

_______________________________________________________________________________

mailto:[email protected]

RFP- 213-10-051-LAB

Addendum No 3

of 4

1) With respect to the existing contract- who is your organization’s

current provider of testing(i.e the incumbent vendor)?

A) South Texas Reference Laboratory/University of Texas Health Science Center in San Antonio.

2) With respect to Solicitation page 13, Section II.G – please clarify

the requirement to sign the UHS Standard Purchase Terms and Conditions with the bid submission. Are bidders required to do this if they identify objections consistent with SectionII.D.5 on PAGE 10?

A) Yes, you are required to sign the T&C’s when submitting your bid. But please provide your specific objections and if your company is selected we can discuss this or negotiate this further.

3) With respect to Solicitation pages 15-16, Section III.1.E- please

clarify your request for examples of all types of reports. Exactly what is required?

A) Reports- UHS would like to examples of any report that might be submitted if Quest Diagnostics wins this bid. This should include but not be limited to: test result reports, quality reports, statistical reports, monthly utilization reports, etc.

4) With respect to Solicitation page 16.III.2.1.B- this section

references promotion of the contract. Does UHS have an outreach sales support team?

A) We do not have an Outreach Program

5) With respect to Solicitation page 17, Section III.2.II.b – this

section indicates that bidders will be providing training to UHS personal and physicians in a variety of areas, including phlebotomy. What kind of phlebotomy support will UHS be requiring from their reference laboratory vendor?

A) Phlebotomy support- Required only to insure that the proper samples are collected in the proper specimen tubes/containers.

RFP- 213-10-051-LAB

Addendum No 3

of 4

6) With respect to Solicitation pages 21-22,III.3.VIII- who is currently served under your outreach program/arrangements?

A) Our clients number less than 50 and consist of hospital,

commercial reference labs and a few miscellaneous entities that are located throughout San Antonio and Central/South Texas.

7) With respect to Solicitation pages 21-22,III.3.VIII-what market does

UHS plan to target for outreach expansion?

A) We currently have no immediate plans to aggressively pursue expanding our current client base.

8) With respect to Solicitation pages 23-27, Attachment A- are the

Histology items (IHC) technical only or do they also include the professional (interpretation) component?

A) This bid will only cover the technical portion.

9) With respect to Solicitation pages 23-27, Attachment A- please

provide a more detailed test description and the current vendor’s test codes for the following items:

RFP- 213-10-051-LAB

Addendum No 3

of 4

A) Specific test information provided below.

Specific test information

Culture Only (AF) Amniotic Fluid Culture

FISH (AF) Fluorescent In situ Hybridization, Amniotic Fluid

FISH (PB Met) Fluorescent In situ Hybridization, Periferal Blood, Metaphass analysis

RCA (AF AFP) Routine Chromosome Analysis, Amniotic Fluid

RCA (AF) Routine Chromosome Analysis, Amniotic Fluid

RCA (PB Mos) Routine Chromosome Analysis, Periferal Blood/Mosaicism Analysis

RCA (PB) Routine Chromosome Analysis, Periferal Blood

RCA (POC) Routine Chromosome Analysis, Products of Conception

Molecular sequencing This was included on the list in error. Please do not respond to this one.

Mould Mold identification

FISH (BM Panel) Fluorescent In situ Hybridization, Bone Marrow. Probes: BCR/ABL, PML-RARA, IGH/BLC2, cMYC.

FISH (BM Single)

Fluorescent In situ Hybridization, Bone Marrow. Order for any one of Probes: BCR/ABL, PML-RARA,

IGH/BLC2, cMYC.

Flow Cytometer Each

Order for one of any of the Immunophenotypic markers: CD2,CD3, CD4, CD5, CD7, CD8, CD10, CD11b,

CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD22, CD23, CD25, CD33, CD34, CD38, CD41a, CD45,

CD56, CD57, CD71, CD117, CD138, KAPPA, LAMBDA, HLA-DR, FMC-7, TCRαβ, TCRγδ, TDT, MPO, Zap 70,

IgG1/IgG2

Limited Panel-FNA CD3, CD4, CD5, CD8, CD10, CD16, CD19, CD34, CD45, CD56, KAPPA, LAMBDA, HLA-DR

Limited Panel-MM (Multiple Myeloma)cKAPPA/cLAMBDA, CD19, CD45, CD56, CD138




FLOOR

355-2 SPENCER LANE



ADDENDUM NO. 2


Due: On or before Novemeber 22, 2013 at 2:00 PM CST

NOTICE TO BIDDERS:









Company Name: ________________________________________________________

__________________________________ _________________________________


_______________________________________________________________________________


RFP- 213-10-051-LAB

Addendum No 2

Page 2 of 2

1) Can UHS please provide the RFP documents in Word and /or Excel

formats to help us to provide the best response possible?

A) Yes, documents were provided when Addendum 1 was sent out via e-mail.

2) Please provide additional information for the attached list of tests

so we can provide the most accurate matches and pricing.

A) Additional information (answers) are provided below as “Q & A to questions 2-Addendum 2”. These Q&A will also be sent via e-mail in legal format.

Q&A to question 2- Addendum 2

Hospital/Clinic CPT Code Procedure Description

12 Month

volume

Dec 1 -

Nov 30

2013

Unit Price Questions Answers

University Health System - Histology 88313 PAM 385 Can you clarify which stain this is? Periodic Acid Methenamone

University Health System - Histology 88184 B-cell tube- add on 3 Is this part of another test?

B-Cell Lymphoma Panel. Probes: t

(14; 18) IGH/BCL2, 8q

rearrangement cMYC, 3q

rearrangement BCL6.

University Health System - Histology 88184 Limited Panel - FNA 5 What is this panel comprised of?

Limited Panel-FNA: CD3, CD4, CD5,

CD8, CD10, CD16, CD19, CD34, CD45,

CD56, KAPPA, LAMBDA, HLA-DR

University Health System - Histology 88184 Limited Panel - MM 7 What is this panel comprised of?

Limited Panel-MM (Multiple

Myeloma): cKAPPA/cLAMBDA, CD19,

CD45, CD56, CD138

University Health System - Histology 88314 Esterase Panel Item 15 Additional information is needed in order to match this.

This is a histochemical enzyme used

to identify "Type 1 fibers in fresh

muscle specimens. It is one test of a

Panel that includes also: Alpha

Naphtyl Acetate and Paraosanniline.

University Health System - Histology 88342 Immunocytochemistry 9 Which test does this refer to?

Immunohistochemistry testing done

on cell block (versus surgical block).

The testa are rarely ordered: TTFI

and Napsin.

University Health System - Histology 88342 MAC 2 Which test does this refer to?

Complement Membrane Attack

Correlation. Used on muscle

specimen (Test: C56-9)

University Health System - Histology 88342 MELANOMA COCKTAIL 60 What is this panel comprised of?

Also known as: Pan Melanoma

Cocktail. Consists of: HMB45,

MART1, Tyrosinase.

University Health System - Histology 88184 Residual B-ALL 3 Is this part of another test?

Test ordered to determine whether

any more cancer cells are left, hence:

"residual" cancer cells.

University Health System - Histology 88233 Tissue culture for non-neoplastic dis 3 Additional information is needed in order to match this.

Testing performed on fetus or

placenta tissue for culture cells.

University Health System - Hematology 8834852 Electron Microscopy, Platelet Study 15 Additional information is needed in order to match this. EM on plasma cells.

University Health System - Histology 88314 Succinic Dehydrogenase/Cytochror 2 Additional information is needed in order to match this.

Testing on muscle tissue.

Mitochondial enzymes: Succinic

(SDH) and Cytochrome Oxidase

(COX)

University Health System - Hematology 8823752 FISH (BM Panel) 54 What is this panel comprised of?

Fluorescent In situ Hybridization,

Bone Marrow. Probes: BCR/ABL,

PML-RARA, IGH/BLC2, cMYC.

University Health System - Hematology 8823752 FISH (BM Single) 30 What is this panel comprised of?

A sngle order for any of the

Fluorescent In situ Hybridization,

Bone Marrow. Probes: BCR/ABL,

PML-RARA, IGH/BLC2, cMYC.

University Health System - Chemistry 88230 Tissue culture for non-neoplastic dis 3 Additional information is needed in order to match this.

Testing performed on fetus or

placenta tissue for culture cells.

University Health System Micro 87188 Micafungin 2 Additional information is needed in order to match this. Antifungal drug level

University Health System Micro 87153 Molecular Sequencing 3 Which test does this refer to?

This was included on the list in error.

Please do not respond to this one.




FLOOR

355-2 SPENCER LANE



ADDENDUM NO. 1


Due: On or before Novemebr 22, 2013 at 2:00 PM CST

NOTICE TO BIDDERS:









Company Name: ________________________________________________________

__________________________________ _________________________________


_______________________________________________________________________________


RFP- 213-10-051-LAB

Addendum No 1

Page 2 of 2

1) Our legal team had comments on the Standard Purchase Terms and Conditions. Should we hold on to these and only submit questions in the event we are chosen, or would you like those immediately as well?

A) Please use the questions form provided in the RFP packet to submit any questions you have on the Purchase terms and conditions.

2) RFP-213-10-051-LAB Page 19 of 22,3. ADDITIONAL INFORMATION,I.Connectivity,D.Attachement C…We were not able to locate Attachement C. in our packet. Can that be provided?

A) Yes, the excel copy will be e-mailed to everyone. 3) RFP-213-10-051-LAB Page 21 of 22,C. Courier Service; There is more than one option that Mayo can provide. Does UHS want the courier to pack the boxes or will the boxes be prepared by send outs picked up by the courier service?

A) Courier- The boxes will be prepared by UHS for pick up by MAYO. 4) Attachment A: Our test mix team had some questions on the test mix that was provided. We want to make sure we are providing and matching up the exact test but some seem to be split. I have attached a list of their questions as they took out the bulk of the test mix and tried to narrow the focus so as not to cause confusion pn their questions.

A) Questions and Answers attached as Attachment A.

Questions for question # 4 (Attachment A)

Questions to /Clarification needed from San Antonio University Health System

The mix provided is broken out by CPT. This format does not provide a “true” picture of laboratory tests being ordered. From the mix provided we have the following questions on how to proceed.

1. Stains – Are stains wanted as Technical Component only (read out and reporting by client pathologist) or as part of a Pathology consultation done at Mayo (includes complete report, interpretation and stain selection by Mayo pathologist)?

2. Flow cytometry – How many cases are ordered by the client site? Mayo testing is provided in an initial triage package based on specimen type. The screening panel will be charged based on number of markers tested (80997 for first marker, 81047 for each additional marker). The interpretation will be set based on markers tested in increments of 9 to 15, or 16 and greater. In addition, reflex testing may occur to fully characterize a disease state or clarify any abnormalities from the screening test. Reflex tests will be performed at an additional charge for each marker tested (80997 if applicable, 81047 if applicable). Mayo does also offer an option for Mayo to complete technical component only – interpretation provided by client pathologist. Which format is wanted by the client?

3. Duplication of some entries - Some volumes appear to be duplicate under different section headings and we need to verify if they are indeed representing correct volumes.

88184 LEUCOCOUNT 357 88184 LEUCOCOUNT 357

One appears in Blood Bank and second in Hematology

88184 LIMITED PANEL -FNA 5 88184 LIMITED PANEL - MM 7

These appear in Histology section

88184 LIMITED PANEL -FNA 5 88184 LIMITED PANEL - MM 7

These appear in Hematology section

4. Abbreviations – Please provide more information for the following: RCA, EBER (ASR), PAM, EM TEM

88235 RCA (AF AFP) 3 88235 RCA (AF) 15 88237 RCA (BM) 112 88237 RCA (LN) 44 88237 RCA (LN) 9 88230 RCA (PB MOS) 3 88230 RCA (PB) 119 88233 RCA (POC) 56 88233 RCA (POC) 9 88233 RCA (POC) 3 88233 RCA (TUMOR) 12 88365 EBER (ASR) 100

88313 PAM

385

5. Some items have the additional information included that they are part of a panel. Could the panels ordered be clarified? The best format for this information is to provide the orderable test name with volume ordered and then a listing of panel members.

CPT Code Test Name Volume

88346 C4D (ONLY) (RUO) PANEL ITEM 20 88342 CD20-MUSCLE PANEL ITEM 15 88342 CD3-MUSCLE PANLE ITEM 15 88342 CD68-MUSCLE PANEL ITEM 15 88314 ESTERASE PANEL ITEM 15 8823752 FISH (BM PANEL) 18 88305 H & E PANEL ITEM 55 88346 IF-IgA PANEL ITEM 140 88346 IF-IgG PANEL ITEM 140 88184 LIMITED PANEL -FNA 5 88184 LIMITED PANEL - MM 7 88184 LYMPHOMA PANEL 105 88184 LYMPHOMA PANEL ADDITIONAL 1 TUBE 9 88314 OIL RED O PANEL ITEM 15 88184 ACUTE LEUKEMIA PANEL 111 88184 ACUTE LEUKEMIA PANEL 12 88184 ACUTE LEUKEMIA PANEL ADDITIONAL 1 6 88184 ACUTE LEUKEMIA PANEL ADDITIONAL 2 21 88184 ACUTE LEUKEMIA PANEL ADDITOINAL 2 6 8823752 FISH (BM PANEL) 54 88184 LIMITED PANEL -FNA 5 88184 LIMITED PANEL- MM 7 88184 LYMPHOMA PANEL - ADD ON 3 88184 LYMPHOMA PANEL 40

6. Information provided is too vague to provide a test match for some.

88342 IMMUNOCYTOCHEMISTRY 9 G0452 MOLECULAR PATHOLOGY INTERPRETATION 200 G0452 MOLECULAR PATHOLOGY INTERPRETATION 84 87153 MOLECULAR SEQUENCING 3 88184 FLOW CYTOMETRY EACH 3

87107 MOULD 3

Answers to question 4.(Attachment A)

1 Stains Technical component only.

2 Flow Cytometry # of Cases: Acute Leukemia: 123/year and Lymphoma: 105/year. Technical component only.

3 Duplications Yes, test volumes that are duplicated by different areas needs to all be included.

4 RCA (AF AFP) / RCA (AF) Routine Chromosome Analysis, Amniotic Fluid

RCA (BM) Routine Chromosome, Bone Marrow

RCA (LN) Routine Chromosome Analysis, Lymph Node

RCA (PB MOS) Routine Chromosome Analysis, Periferal Blood/Mosaicism Analysis

RCA (PB) Routine Chromosome Analysis, Periferal Blood

RCA (POC) Routine Chromosome Analysis, Products of Conception

RCA (TUMOR) Routine Chromosome Analysis, Solid Tumor

EBER (ASR) In situ hybridization: Epstein Bar Virus-encoded RNA (histochemical stain)

PAM Periodic Acid Methenamine Silver staining - Histochemistry Testing

Muscle Panel

H&E-FS, Esterase, Myophosphorylase, NADH, Oil Red O, PAS with and

with-out diastase, Gomori's Trichrome, ATPase 10.4, H&E (paraffin),

CD3, CD20, CD68, Masson's Trichrome and Alkaline Phosphatase.

Immunocytochemistry Immunohistochemistry testing done on cell block (versus surgical block).

Molecular sequencing This was included on the list in error. Please do not respond to this one.

Acute Leukemia Panel

CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD11c, CD13, CD14,

CD15, CD16, CD19, CD20, CD22, CD23, CD25, CD33, CD34, CD41a,

CD45, CD56, CD57, CD71, CD117, CD138, KAPPA, LAMBDA, HLA-DR,

FMC-7

Lymphoma Panel

CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD16, CD19, CD20, CD22,

CD23, CD25, CD34, CD45, CD56, CD57, CD138, KAPPA, LAMBDA, HLA-

DR, FMC-7

Limited Panel-FNA CD3, CD4, CD5, CD8, CD10, CD16, CD19, CD34, CD45, CD56, KAPPA, LAMBDA, HLA-DR

Limited Panel-MM (Multiple Myeloma) cKAPPA/cLAMBDA, CD19, CD45, CD56, CD138

FISH (BM Panel) Fluorescent In situ Hybridization, Bone Marrow. Probes: BCR/ABL, PML-RARA, IGH/BLC2, cMYC.

d nd f s l a tx - university health systemhr.universityhealthsystem.com/purchasing/pdf/918a.pdf ·...

Documents